189 related articles for article (PubMed ID: 32921792)
1. Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours.
Nonaka M; Suzuki-Anekoji M; Nakayama J; Mabashi-Asazuma H; Jarvis DL; Yeh JC; Yamasaki K; Akama TO; Huang CT; Campos AR; Nagaoka M; Sasai T; Kimura-Takagi I; Suwa Y; Yaegashi T; Shibata TK; Sugihara K; Nishizawa-Harada C; Fukuda M; Fukuda MN
Br J Cancer; 2020 Nov; 123(11):1633-1643. PubMed ID: 32921792
[TBL] [Abstract][Full Text] [Related]
2. Tumor vasculature-targeted
Yoneyama T; Hatakeyama S; Sutoh Yoneyama M; Yoshiya T; Uemura T; Ishizu T; Suzuki M; Hachinohe S; Ishiyama S; Nonaka M; Fukuda MN; Ohyama C
BMC Cancer; 2021 Jan; 21(1):72. PubMed ID: 33446132
[TBL] [Abstract][Full Text] [Related]
3. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Hatakeyama S; Sugihara K; Shibata TK; Nakayama J; Akama TO; Tamura N; Wong SM; Bobkov AA; Takano Y; Ohyama C; Fukuda M; Fukuda MN
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19587-92. PubMed ID: 22114188
[TBL] [Abstract][Full Text] [Related]
4. Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides.
Nonaka M; Mabashi-Asazuma H; Jarvis DL; Yamasaki K; Akama TO; Nagaoka M; Sasai T; Kimura-Takagi I; Suwa Y; Yaegashi T; Huang CT; Nishizawa-Harada C; Fukuda MN
PLoS One; 2021; 16(1):e0241157. PubMed ID: 33406123
[TBL] [Abstract][Full Text] [Related]
5. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
6. Identification of two phosphorylation sites essential for annexin A1 in blood-brain barrier protection after experimental intracerebral hemorrhage in rats.
Wang Z; Chen Z; Yang J; Yang Z; Yin J; Zuo G; Duan X; Shen H; Li H; Chen G
J Cereb Blood Flow Metab; 2017 Jul; 37(7):2509-2525. PubMed ID: 27634935
[TBL] [Abstract][Full Text] [Related]
7. Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis.
Pan Y; Zhong LJ; Zhou H; Wang X; Chen K; Yang HP; Xiaokaiti Y; Maimaiti A; Jiang L; Li XJ
Acta Pharmacol Sin; 2012 Jun; 33(6):798-808. PubMed ID: 22669117
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells.
Hyoudou K; Nishikawa M; Umeyama Y; Kobayashi Y; Yamashita F; Hashida M
Clin Cancer Res; 2004 Nov; 10(22):7685-91. PubMed ID: 15570002
[TBL] [Abstract][Full Text] [Related]
9. Annexin A1 restores Aβ
Park JC; Baik SH; Han SH; Cho HJ; Choi H; Kim HJ; Choi H; Lee W; Kim DK; Mook-Jung I
Aging Cell; 2017 Feb; 16(1):149-161. PubMed ID: 27633771
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting by a carbohydrate ligand-mimicking peptide.
Hatakeyama S; Shibata TK; Tobisawa Y; Ohyama C; Sugihara K; Fukuda MN
Methods Mol Biol; 2013; 1022():369-86. PubMed ID: 23765676
[TBL] [Abstract][Full Text] [Related]
11. CCR7 regulates B16 murine melanoma cell tumorigenesis in skin.
Fang L; Lee VC; Cha E; Zhang H; Hwang ST
J Leukoc Biol; 2008 Oct; 84(4):965-72. PubMed ID: 18519742
[TBL] [Abstract][Full Text] [Related]
12. Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination.
Rondepierre F; Bouchon B; Papon J; Bonnet-Duquennoy M; Kintossou R; Moins N; Maublant J; Madelmont JC; D'Incan M; Degoul F
Biochim Biophys Acta; 2009 Jan; 1794(1):61-9. PubMed ID: 18952200
[TBL] [Abstract][Full Text] [Related]
13. Tumours can act as adjuvants for humoral immunity.
Brown DM; Fisher TL; Wei C; Frelinger JG; Lord EM
Immunology; 2001 Apr; 102(4):486-97. PubMed ID: 11328383
[TBL] [Abstract][Full Text] [Related]
14. Annexin A1 protects against cerebral ischemia-reperfusion injury by modulating microglia/macrophage polarization via FPR2/ALX-dependent AMPK-mTOR pathway.
Xu X; Gao W; Li L; Hao J; Yang B; Wang T; Li L; Bai X; Li F; Ren H; Zhang M; Zhang L; Wang J; Wang D; Zhang J; Jiao L
J Neuroinflammation; 2021 May; 18(1):119. PubMed ID: 34022892
[TBL] [Abstract][Full Text] [Related]
15. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
[TBL] [Abstract][Full Text] [Related]
16. SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy.
Huang Y; Wang L; Cheng Z; Yang B; Yu J; Chen Y; Lu W
J Control Release; 2021 Nov; 339():297-306. PubMed ID: 34619226
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.
García-Hernández ML; Hernández-Pando R; Gariglio P; Berumen J
Immunology; 2002 Feb; 105(2):231-43. PubMed ID: 11872099
[TBL] [Abstract][Full Text] [Related]
18. Burst release of encapsulated annexin A5 in tumours boosts cytotoxic T-cell responses by blocking the phagocytosis of apoptotic cells.
Li L; Zou J; Dai Y; Fan W; Niu G; Yang Z; Chen X
Nat Biomed Eng; 2020 Nov; 4(11):1102-1116. PubMed ID: 32807941
[TBL] [Abstract][Full Text] [Related]
19. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.
Zhang B; Sun X; Mei H; Wang Y; Liao Z; Chen J; Zhang Q; Hu Y; Pang Z; Jiang X
Biomaterials; 2013 Dec; 34(36):9171-82. PubMed ID: 24008043
[TBL] [Abstract][Full Text] [Related]
20. Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines.
Miwa T; Kanda M; Umeda S; Tanaka H; Shimizu D; Tanaka C; Kobayashi D; Hayashi M; Yamada S; Nakayama G; Koike M; Kodera Y
In Vivo; 2019; 33(6):1785-1792. PubMed ID: 31662503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
